Adverum Biotechnologies Announces Positive Results in Preclinical Study of ADVM-022 Gene Therapy in Wet AMD

Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced long-term preclinical efficacy data on ADVM-022 in a non-human primate model of wet age-related macular degeneration (wAMD).